parkinson disease
Conditions
Interventions
Treatment group:acupuncture at DU20, DU17, DU16, GB20, DU14, DU11, DU9, DU4, DU3
Control group:Shallow acupuncture at sham acupoint
Sponsors
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Eligibility
Sex/Gender
All
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The patients met the diagnostic criteria of DPD in "Guidelines for the Diagnosis and Treatment of Depression, Anxiety and Psychotic Disorders in Parkinson's Disease"; 2. The age ranged from 50 to 75 years; 3. According to the evaluation by the PD-specific disease clinic of the Neurology department of the research cooperation unit, the patients had received standardized anti-PD drugs for at least 3 months, and had a fixed anti-PD drug treatment plan, and no drug adjustment plan in the next 3 months; 4. H-Y stage 7 points, and <= 24 points; 6. The patients had not received acupuncture treatment for DPD or PD in the past 3 months; 7. No language and mental retardation (mini-mental State examination (MMSE)), can successfully complete the assessment of DPD related scales; 8. Participating voluntarily in the study and have signed informed consent to treatment.
Exclusion criteria
Exclusion criteria: 1. Patients with secondary Parkinson's syndrome or Parkinsonism-Plus syndrome; 2. Patients who are currently taking or have taken traditional antidepressants in the past 2 weeks, such as selective serotonin and norepinephrine reuptake inhibitors (venlafaxine, etc.), selective serotonin reuptake inhibitors (sertraline, paroxetine, fluoxetine, citalopram, etc.), tricyclic antidepressants (amitriptyline, etc.); 3. Patients undergoing neurosurgical (deep brain stimulation) treatment, psychotherapy, or repetitive transcranial magnetic stimulation; 4. Patients with serious medical diseases such as heart, liver, kidney, hematopoietic system disorders or malignant tumors, and mental disorders; 5. Patients who cannot receive fMRI scan for other reasons; 6. Patients who are participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The response rate of Hamilton Depression Scale-17; | — |
Secondary
| Measure | Time frame |
|---|---|
| resting-state fMRI;The response rate of Hamilton Depression Scale-17;The response rate of Hamilton Depression Scale-17;Unified Parkinson's disease rating scale section III ;Unified Parkinson's disease rating scale section III X;Unified Parkinson's disease rating scale section III ;Quick inventory of depressive symptomatology-self report ;Quick inventory of depressive symptomatology-self report ;Quick inventory of depressive symptomatology-self report;Parkinson’s Disease Questionnaire-39 ;Parkinson’s Disease Questionnaire-39 ;Parkinson’s Disease Questionnaire-39 ;The proportion of patients with progressive H-Y staging ; | — |
Countries
China
Contacts
Public ContactChen Peng
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Outcome results
None listed